logo
Plus   Neg
Share
Email

Coca-Cola Q1 Profit Grows - Quick Facts

Beverages giant Coca-Cola Co. (KO) reported a rise in its first quarter 2012 net income attributable to shareowners of the company to $2.05 billion from $1.90 billion, with reported GAAP earnings per share improving to $0.89 from $0.82 in the earlier year quarter. On average, 14 analysts polled by Thomson Reuters expected earnings per share of $0.87 for the quarter. Analysts' estimates typically exclude one-time items.

Items affecting comparability had no net impact on first quarter 2012 reported earnings per share and reduced last year's reported earnings per share by $0.04 per share, the company said.

Quarterly net operating revenues totaled $11.14 billion, up 6% from $10.52 billion, as adjusted, a year ago. Both reported and comparable net revenue for the recent quarter grew 6%, helped by a 3% rise in concentrate sales, positive price/mix of 3%, driven mainly by positive pricing, and a 1% positive impact due to structural change. Eleven analysts estimated revenues of $10.83 billion for the quarter.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT